Kera Capital Partners Inc. Makes New Investment in Illumina, Inc. $ILMN

Key Points

• Kera Capital Partners Inc. invested approximately $387,000 in Illumina, acquiring 4,053 shares during the 2nd quarter.
• Several institutional investors increased their stakes in Illumina, with 89.42% of the stock owned by institutional investors, indicating significant market confidence.
• Analysts have mixed ratings on Illumina, with a consensus rating of "Hold" and a target price averaging $123.06.

Kera Capital Partners Inc. bought a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 4,053 shares of the life sciences company's stock, valued at approximately $387,000.

Several other large investors also recently added to or reduced their stakes in ILMN. Rise Advisors LLC grew its position in Illumina by 173.6% in the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company's stock worth $28,000 after acquiring an additional 224 shares in the last quarter. Rakuten Securities Inc. grew its position in Illumina by 290.3% in the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock worth $29,000 after acquiring an additional 270 shares in the last quarter. Center for Financial Planning Inc. bought a new stake in Illumina in the first quarter worth approximately $33,000. Fourth Dimension Wealth LLC bought a new stake in Illumina in the fourth quarter worth approximately $40,000. Finally, PFS Partners LLC grew its position in Illumina by 400.0% in the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock worth $40,000 after acquiring an additional 400 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Daiwa Capital Markets downgraded shares of Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price objective for the company. in a report on Tuesday, August 12th. Daiwa America downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 12th. Morgan Stanley upped their price objective on shares of Illumina from $100.00 to $105.00 and gave the stock an "equal weight" rating in a report on Monday, August 4th. Stephens set a $110.00 price objective on shares of Illumina and gave the stock an "overweight" rating in a report on Monday, August 4th. Finally, Scotiabank downgraded shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price objective for the company. in a report on Friday, July 11th. Six equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $123.06.

Illumina Price Performance

NASDAQ:ILMN opened at $95.12 on Friday. The stock has a market cap of $14.62 billion, a P/E ratio of 12.04, a PEG ratio of 2.23 and a beta of 1.43. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The company has a fifty day moving average price of $99.46 and a 200 day moving average price of $88.53. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.02 by $0.17. The firm had revenue of $1.06 billion during the quarter, compared to analysts' expectations of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business's quarterly revenue was down 4.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.